DNX Biopharmaceuticals Announces Collaboration with Lung Cancer Initiative at Johnson & Johnson
配信日時: 2020-02-19 02:00:00
SAN DIEGO, CA, Feb 19, 2020 - ( JCN Newswire ) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS @ Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to research, develop and commercialize novel molecules from within the DNX portfolio. Financial terms of the collaboration were not disclosed.
"We are delighted to be collaborating with the Lung Cancer Initiative at Johnson & Johnson," said Rajiv Datar, Ph.D., co-founder and CEO of DNX. "We look forward to progressing DNX's novel molecules into clinical development."
"Our collaboration with the Lung Cancer Initiative at Johnson & Johnson was fostered by being an awardee of the Lung Cancer Innovation QuickFire Challenge and receiving residency at Johnson & Johnson Innovation - JLABS @ Shanghai," commented Dr. Carl Edwards III, CSO of DNX. "We are now looking forward to establishing our Asia-Pacific Research and Development capabilities in Shanghai, which will be wholly dedicated to Cancer Immunotherapy."
About DNX Biopharmaceuticals, Inc.
Founded in 2014 and headquartered in San Diego, California, USA, DNX is a biopharmaceutical company developing non-immunogenic, long-acting biologic therapies for the treatment of patients with life-long diseases linked to inflammation, autoinflammation and oncology. As an awardee of the Lung Cancer Innovation QuickFire Challenge, DNX received residency at Johnson & Johnson Innovation - JLABS @ Shanghai. At JLABS Shanghai, DNX will pursue an ongoing R&D effort that leverages its intrinsically disordered protein technologies designed to explore the tumor microenvironment, leading to the identification of novel pathways that can be targeted with molecules to substantially influence "anti-tumoral" therapeutic responses. Ongoing nonclinical efforts have identified several novel candidates that may act as "Immune Checkpoint Inhibitors" alone or in combination with existing standard of care anti-PD-1 and CTLA-4 therapies to reverse CD8+ T cell functions, all with the aim of improving clinical outcomes across the vast range of cancer conditions. For more information, please visit www.dnxbio.com.
*Johnson & Johnson Enterprise Innovation Inc. is the legal entity to the agreement.
Media Contact:
Claude Gingras, CFO
Claude.Gingras@dnxbio.com
Related Links
- J&J Announcement of the Winners of the Lung Cancer QuickFire Award
https://www.newsfilecorp.com/redirect/XmpnIyDP
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52493
スポンサードリンク
「ビジネス全般」のプレスリリース
スポンサードリンク
最新のプレスリリース
- ノジマTリーグ 2023-2024シーズン 2024パリオリンピックシングルス選考ポイント 獲得状況 (11/5 開催終了時)11/08 21:45
- マレーシアの方々と運動会で交流!「スポーツダイバーシティフェスティバル2023」―参加者募集中!11/08 21:45
- 「幻想神域 -Another Fate-」限定イベントや世界ボスを含む「10周年記念イベント第2弾」を開催!ダンジョンドロップやスキルのアップデートを実施!11/08 21:45
- ノジマTリーグ 2023-2024シーズン 11月3,4,5日 試合結果振り返り&次週開催予定11/08 21:45
- ドローンを使った効率的なインフラ点検や捜索、救助での活用がわかる無料実演会を11月21日(火)に滋賀県長浜市で開催11/08 21:45
- 最新のプレスリリースをもっと見る